Research programme: anticancer prodrugs - Threshold Pharmaceuticals

Drug Profile

Research programme: anticancer prodrugs - Threshold Pharmaceuticals

Alternative Names: HAP; Hypoxia-activated prodrug technology - Threshold; OBI-3424; TH-3424

Latest Information Update: 13 Jun 2017

Price : $50

At a glance

  • Originator Threshold Pharmaceuticals
  • Developer National Cancer Institute (USA); Threshold Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action AKR1C3 protein inhibitors; Alkylating agents; DNA cross linking agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Acute lymphoblastic leukaemia; Hepatocellular carcinoma; Pancreatic cancer

Most Recent Events

  • 01 Jun 2017 OBI-Pharma plans to acquire TH 3424 from Threshold Pharma
  • 23 Jan 2017 Preclinical trials in Acute lymphoblastic leukaemia in Australia (unspecified route) (Threshold Pharmaceuticals pipeline, January 2017)
  • 23 Jan 2017 Preclinical trials in Pancreatic cancer in USA (unspecified route) (Threshold Pharmaceuticals pipeline, January 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top